These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16258472)

  • 21. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
    Dreyling M; Hiddemann W
    Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
    Christopeit M; Haak U; Behre G
    Ann Hematol; 2008 Sep; 87(9):761-2. PubMed ID: 18350295
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab.
    Rey J; Belmecheri N; Bouayed N; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
    Haematologica; 2007 Oct; 92(10):e101. PubMed ID: 18024364
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete response in a patient with colonic mantle cell lymphoma with multiple lymphomatous polyposis treated with combination chemotherapy using anti-CD20 antibody and cladribine.
    Watanabe T; Homma N; Ogata N; Saito H; Kanefuji T; Hasegawa K; Soga K; Shibasaki K; Endo T; Ajioka Y
    Gut; 2007 Mar; 56(3):449-50. PubMed ID: 17339260
    [No Abstract]   [Full Text] [Related]  

  • 26. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.
    Vallet S; Tempescul A; Tran A; Legrand-Quillien MC; Narbonne V; Berthou C
    Ann Hematol; 2005 Aug; 84(8):545-7. PubMed ID: 15789227
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
    Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.
    Villanueva ML; Vose JM
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):521-30. PubMed ID: 17147239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
    Hanamura A; Hayakawa M; Naito K
    Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?
    Smith SD; Sweetenham JW
    Leuk Lymphoma; 2010 Mar; 51(3):357-9. PubMed ID: 20148757
    [No Abstract]   [Full Text] [Related]  

  • 32. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review: stem cell transplantation for mantle cell lymphoma: not yet the standard of care.
    Sweetenham JW
    Clin Adv Hematol Oncol; 2009 May; 7(5):323-4. PubMed ID: 19521321
    [No Abstract]   [Full Text] [Related]  

  • 34. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bilateral panocular involvement with mantle-cell lymphoma.
    Chappelow AV; Singh AD; Perez VL; Lichtin A; Pohlman B; Macklis R
    J Clin Oncol; 2008 Mar; 26(7):1167. PubMed ID: 18309953
    [No Abstract]   [Full Text] [Related]  

  • 36. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mantle cell lymphoma: new treatments targeted to the biology.
    Bertoni F; Ghielmini M; Cavalli F; Cotter FE; Zucca E
    Clin Lymphoma; 2002 Sep; 3(2):90-6. PubMed ID: 12435282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.